188 related articles for article (PubMed ID: 19208827)
1. Effect of hypoxia on the expression of phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in non-small cell lung carcinoma.
Lam W; Bussom S; Cheng YC
Mol Cancer Ther; 2009 Feb; 8(2):415-23. PubMed ID: 19208827
[TBL] [Abstract][Full Text] [Related]
2. The impact of hypoxic treatment on the expression of phosphoglycerate kinase and the cytotoxicity of troxacitabine and gemcitabine.
Lam W; Leung CH; Bussom S; Cheng YC
Mol Pharmacol; 2007 Sep; 72(3):536-44. PubMed ID: 17565005
[TBL] [Abstract][Full Text] [Related]
3. Apurinic/apyrimidinic endonuclease-1 protein level is associated with the cytotoxicity of L-configuration deoxycytidine analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine) but not D-configuration deoxycytidine analogs (gemcitabine and beta-D-arabinofuranosylcytosine).
Lam W; Park SY; Leung CH; Cheng YC
Mol Pharmacol; 2006 May; 69(5):1607-14. PubMed ID: 16481390
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
5. A novel action of human apurinic/apyrimidinic endonuclease: excision of L-configuration deoxyribonucleoside analogs from the 3' termini of DNA.
Chou KM; Kukhanova M; Cheng YC
J Biol Chem; 2000 Oct; 275(40):31009-15. PubMed ID: 10906132
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor activity of troxacitabine and camptothecin in selected human cancer cell lines.
Kim TE; Park SY; Hsu CH; Dutschman GE; Cheng YC
Mol Pharmacol; 2004 Aug; 66(2):285-92. PubMed ID: 15266019
[TBL] [Abstract][Full Text] [Related]
7. Synergistic activity of troxacitabine (Troxatyl) and gemcitabine in pancreatic cancer.
Damaraju VL; Bouffard DY; Wong CK; Clarke ML; Mackey JR; Leblond L; Cass CE; Grey M; Gourdeau H
BMC Cancer; 2007 Jul; 7():121. PubMed ID: 17608948
[TBL] [Abstract][Full Text] [Related]
8. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
9. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
10. The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.
Weitman S; Marty J; Jolivet J; Locas C; Von Hoff DD
Clin Cancer Res; 2000 Apr; 6(4):1574-8. PubMed ID: 10778991
[TBL] [Abstract][Full Text] [Related]
11. Anticancer activity of beta-L-dioxolane-cytidine, a novel nucleoside analogue with the unnatural L configuration.
Grove KL; Guo X; Liu SH; Gao Z; Chu CK; Cheng YC
Cancer Res; 1995 Jul; 55(14):3008-11. PubMed ID: 7606719
[TBL] [Abstract][Full Text] [Related]
12. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
13. Action of troxacitabine on cells transduced with human cytidine deaminase cDNA.
Boivin AJ; Gourdeau H; Momparler RL
Cancer Invest; 2004; 22(1):25-9. PubMed ID: 15069761
[TBL] [Abstract][Full Text] [Related]
14. In vitro optimization of non-small cell lung cancer activity with troxacitabine, L-1,3-dioxolane-cytidine, prodrugs.
Radi M; Adema AD; Daft JR; Cho JH; Hoebe EK; Alexander LE; Peters GJ; Chu CK
J Med Chem; 2007 May; 50(9):2249-53. PubMed ID: 17419604
[TBL] [Abstract][Full Text] [Related]
15. Beta-L-1,3-dioxolane-cytidine: a novel nucleoside that inhibits proliferation and induces differentiation of keratinocytes in vitro.
Schwartz PM; Haggerty JG; Cheng YC
Skin Pharmacol Appl Skin Physiol; 1998; 11(4-5):207-13. PubMed ID: 9885404
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models.
Higgins B; Kolinsky K; Smith M; Beck G; Rashed M; Adames V; Linn M; Wheeldon E; Gand L; Birnboeck H; Hoffmann G
Anticancer Drugs; 2004 Jun; 15(5):503-12. PubMed ID: 15166626
[TBL] [Abstract][Full Text] [Related]
17. Preclinical pharmacokinetics of beta-L-dioxolane-cytidine, a novel anticancer agent, in rats.
Moore LE; Boudinot FD; Chu CK
Cancer Chemother Pharmacol; 1997; 39(6):532-6. PubMed ID: 9118465
[TBL] [Abstract][Full Text] [Related]
18. Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts.
Iwai T; Moriya Y; Shirane M; Fujimoto-Ouchi K; Mori K
Oncol Rep; 2012 Apr; 27(4):923-8. PubMed ID: 22209766
[TBL] [Abstract][Full Text] [Related]
19. Species differences in troxacitabine pharmacokinetics and pharmacodynamics: implications for clinical development.
Gourdeau H; Leblond L; Hamelin B; Dong K; Ouellet F; Boudreau C; Custeau D; Richard A; Gilbert MJ; Jolivet J
Clin Cancer Res; 2004 Nov; 10(22):7692-702. PubMed ID: 15570003
[TBL] [Abstract][Full Text] [Related]
20. Role of deoxycytidine kinase (dCK), thymidine kinase 2 (TK2), and deoxycytidine deaminase (dCDA) in the antitumor activity of gemcitabine (dFdC).
Kroep JR; van Moorsel CJ; Veerman G; Voorn DA; Schultz RM; Worzalla JF; Tanzer LR; Merriman RL; Pinedo HM; Peters GJ
Adv Exp Med Biol; 1998; 431():657-60. PubMed ID: 9598147
[No Abstract] [Full Text] [Related]
[Next] [New Search]
